Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20 + non-Hodgkin Lymphoma

Ian W. Flinn, MD PhD, Jason R. Westin, MD, Jonathon B. Cohen, MDMS, Luke P. Akard, MD, Samantha Jaglowski, MDMPH, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Veronika Bachanova, MD PhD

Blood (2019) 134 (Supplement_1): 1587.

https://doi.org/10.1182/blood-2019-125995

Published: 2019

Journal Articles

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Javier Munoz, MD, Samantha Jaglowski, MDMPH, Matthew S. McKinney, MD, Iris Isufi, MD, Patrick J. Stiff, MD, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Luke P. Akard, MD

Blood (2019) 134 (Supplement_1): 244.

https://doi.org/10.1182/blood-2019-123810

Published: 2019

Journal Articles

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Don M. Benson, Jr., MD PhD, Houston Holmes, MD, Parameswaran Hari, MBBS, MD, Jessica Sachs, MD, Ben Exter, Ann Ranger, PhD, Tooba Cheema, PhD, Iga Sienczylo, BS, Megan M. O'Meara, MD, Django Sussman, PhD, Luke P. Akard, MD

Blood (2018) 132 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2018-99-111729

Published: 2018

Journal Articles

Adaptability of Antibody-Coupled T Cell Receptor (ACTR) Engineered Autologous T Cells in Combination with Daratumumab over CAR-Based Approaches

Taylor Hickman, BS, Adrianna Graziano, Katie O'Callaghan, PhD, Ryan Boomer, BA, Eugene Choi, MS, Allison Nelson, BS, Greg Motz, PhD, Jessica Sachs, MD, Birgit Schultes, PhD, Seth Ettenberg, PhD, Tooba Cheema, PhD

Blood (2017) 130 (Supplement 1): 3189.

https://doi.org/10.1182/blood.V130.Suppl_1.3189.3189

Published: 2017

Journal Articles

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Franco Locatelli, MD, Kathleen A Neville, MD, MS, Angelo Rosolen, MD, Judith Landman-Parker, MD, Nathalie Aladjidi, MD, Auke Beishuizen, MD, Stephen Daw, BSc Hons, MBChB, MRCP, Lia Gore, MD, Anna R.K. Franklin, MD, Adedigbo Fasanmade, PhD, Jingyuan Wang, PhD, Jessica Sachs, MD, Christine Mauz-Koerholz, MD

Blood (2013) 122 (21): 4378.

https://doi.org/10.1182/blood.V122.21.4378.4378

Published: 2013

Journal Articles

Lymphopenia Promotes the Development of Graft-Versus-Host Disease upon Donor Leukocyte Infusion.

Jessica Sachs, MD, Megan Sykes, MD

Blood (2007) 110 (11): 2185.

https://doi.org/10.1182/blood.V110.11.2185.2185

Published: 2007

Journal Articles

Requirement for CD4 Help for Optimal GVL Effects of Alloreactive T Cells Given to Established Mixed Chimeras but Not Freshly Irradiated Mice.

Hyeon-Seok Eom, MD, PhD, Ronjon Chakraverty, MD, PhD, Jessica Sachs, MD, Guiling Zhao, Megan Sykes, MD

Blood (2004) 104 (11): 3044.

https://doi.org/10.1182/blood.V104.11.3044.3044

Published: 2004

NARROW

Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20 + non-Hodgkin Lymphoma

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Adaptability of Antibody-Coupled T Cell Receptor (ACTR) Engineered Autologous T Cells in Combination with Daratumumab over CAR-Based Approaches

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Lymphopenia Promotes the Development of Graft-Versus-Host Disease upon Donor Leukocyte Infusion.

Requirement for CD4 Help for Optimal GVL Effects of Alloreactive T Cells Given to Established Mixed Chimeras but Not Freshly Irradiated Mice.

Email alerts

ASH Publications

American Society of Hematology

Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20 + non-Hodgkin Lymphoma

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Adaptability of Antibody-Coupled T Cell Receptor (ACTR) Engineered Autologous T Cells in Combination with Daratumumab over CAR-Based Approaches

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Lymphopenia Promotes the Development of Graft-Versus-Host Disease upon Donor Leukocyte Infusion.

Requirement for CD4 Help for Optimal GVL Effects of Alloreactive T Cells Given to Established Mixed Chimeras but Not Freshly Irradiated Mice.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only